Abstract:Abstract Background: Adenosquamous carcinoma of the pancreas (PASC) is a mixed tumor type which contains squamous cell carcinoma and also ductal adenocarcinoma components. PASC is a rare type representing about 1-4% of the total incidence. Due to the rarity of this malignancy, limited genomic data have been performed. In this study, we analyzed the genomic alterations and clinical signatures of PASC. Materials and Methods: Formalin fixed, paraffin embedded (FFPE) tumor tissues and matched blood samples were collected for targeted next-generation sequencing (NGS) assay at OrigiMed (Shanghai, China), a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations including single base substitution, indel, copy number variations, gene fusions and rearrangement were assessed. Tumor mutational burden (TMB) was also analyzed by NGS algorithm. Alterations in homologous recombination repair (HRR) with PASC were analyzed. Results: In total, 31 PASC patients were recruited included 15 females (48.4%) and 16 males (51.6%) with a media age of 59 years old (range 35-78). A total of 32% (10/31) of patients possessed a confirmed cancer-related family history. The most commonly altered genes were KRAS (97%), TP53 (77%), CDKN2A (35%), SMAD4 (23%), FAT3 (13%), CIC (10%) and SPTA1 (10%). The KEGG pathway analysis revealed that those top mutated genes significantly associated with MAPK signaling pathway. 42% (13/31) of the patients had one or more actionable genomic alterations, including BRCA2, STK11, CDKN2A/B, FGFR and PTEN. Germline mutations were identified in 4 patients (13%), including BRCA2 (2/4), SPINK1 (1/4), FANCA (1/4). The most common mutational type was substitution/Indel (56%), followed by truncation (20%) and gene amplification (17%). Three (10%) patients had at least one mutation in HRR genes, including BRCA2 (2/3) and CHEK2 (1/3).The median TMB of patients with PASC was 3.2 muts/Mb (range, 0.5-9.3 muts/Mb). Patients with STK11 alterations had lower value of TMB than STK11 wild type (median TMB 0.85 vs. 3.37 muts/Mb, respectively, P <0.05). In addition, patients with HRR mutations had a significantly higher TMB value than HRR wild type (7.73 vs. 2.73 muts/Mb, respectively, P <0.01). Conclusion: Our study revealed the genomic profiling of the largest sample size of Chinese PASC patients so far. 42% (13/31) of the patients had one or more actionable genomic alterations. HRR pathway alterations are relatively frequent (10%) in PASC and consideration for biomarker-enriched clinical trials with PARP, immune checkpoint inhibitors, and novel combinations are warranted. Citation Format: Zheng Wang, Xue Yang, Wei Li, Zheng Wu, Qingyong Ma, Xiaofang Qi, Juan Zhao. Genomic profiling of Chinese adenosquamous carcinoma of the pancreas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2659.

Comprehensive Bioinformatical Analysis Identifies Heterogeneity of Genomics and Tumor Microenvironment Between Pancreatic Adenosquamous Carcinoma and Pancreatic Ductal Adenocarcinoma

Comparative study of clinical and imaging features of pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma

Genomics and transcriptomics of pancreatic adenosquamous carcinoma.

Single-cell Transcriptome Reveals the Heterogeneity of Malignant Ductal Cells and the Prognostic Value of REG4 and SPINK1 in Primary Pancreatic Ductal Adenocarcinoma

Analysis of Dynamic Molecular Networks for Pancreatic Ductal Adenocarcinoma Progression

Comparative Bioinformatical Analysis of Pancreatic Head Cancer and Pancreatic Body/Tail Cancer

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes

Abstract 2659: Genomic Profiling of Chinese Adenosquamous Carcinoma of the Pancreas

Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma

Genomic landscape and clonal evolution between adenocarcinoma and squamous components in adenosquamous carcinoma of the pancreas.

Genetic Landscape of Prognostic Value in Pancreas Ductal Adenocarcinoma Microenvironment-Reply.

Genomic signatures of adenosquamous carcinoma of the pancreas (PASC).

A cc ep te d A rti cl e Genomic signatures of adenosquamous carcinoma of the pancreas ( PASC )

Abstract 1587: Multimodal spatial transcriptomics uncover distinct tumor microenvironment states and cell-cell communication networks in molecular pancreatic cancer subtypes

Mutation Profiling Of Cancer And Stromal Cells From Patients With Pancreatic Ductal Adenocarcinoma.

Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target

Elevated Expression of Cell Adhesion, Metabolic, and Mucus Secretion Gene Clusters Associated with Tumorigenesis, Metastasis, and Poor Survival in Pancreatic Ductal Adenocarcinoma

Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression

Single-cell sequencing reveals heterogeneity between pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma with prognostic value

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers